Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Qilu Pharmaceuticals (Qilu) has today received approval for Gefitinib Qilu tablet 250mg in Norway and the product is expected to be approved in Denmark and Sweden soon. Gefitinib Qilu is the first of currently seven pharmaceuticals in which EQL will act as a local representative for Qilu in the Nordic region. As a local representative, EQL buys, stocks and sells pharmaceuticals for Qilu in the Nordic region. Registration of the pharmaceuticals, on the other hand, is done by Qilu and they own all rights and have all obligations a registration brings with it from the Authorities.
Qilu Pharmaceuticals is a leading Chinese pharmaceutical company with eight production facilities, more than 15,000 employees and over 200 products in its range.
Gefitinib Qilu is a so-called protein kinase inhibitor which is used in the treatment of non-small cell lung cancer. The total market in Sweden, Denmark and Norway amounts to approximately SEK 10 million with five active competitors. In Sweden, Gefitinib is an outpatient drug, while in Denmark and Norway it is sold in inpatient care via public procurement. Gefitinib Qilu is expected to be launched in EQL's third financial quarter of 2021/22.
In practice, Gefitinib Qilu will be included in EQL Pharma's portfolio like any other product and the Qilu products' sales and profits will not be reported separately in future financial reports.